Acorda Therapeutics, Inc.
DelistedCIK 1008848fmd_1P40H2GGHKQ7XB0EG0X1DTZR6MManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2008 to Mar 31, 2024, 63 periods
Latest annual · FY2023
Millions- Total revenues
- 118
- Gross profit
- 102
- Operating income
- (265)
- Net income
- (253)
- Free cash flow
- (14)
Latest quarter · Q1 FY2024
Millions- Total revenues
- 20
- Gross profit
- 17
- Operating income
- (20)
- Net income
- (27)
- Free cash flow
- (3)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2020 to FY2023
- -8.4%
- Revenue, 5 yearsFY2018 to FY2023
- -24.2%
- Net income, 5 yearsFY2018 to FY2023
- n/m
Acorda Therapeutics, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2023 | FY2022 | Change | Source |
|---|---|---|---|---|
| Revenue | $117.6 million | $118.6 million | -0.8% | 10-K 2024-04-01 · proof |
| Gross profit | $102.4 million | $88.2 million | +16% | 10-K 2024-04-01 · proof |
| Operating income | -$265 million | -$35.3 million | 10-K 2024-04-01 · proof | |
| Net income | -$252.9 million | -$65.9 million | 10-K 2024-04-01 · proof | |
| Cash from operating activities | -$14 million | -$20.9 million | 10-K 2024-04-01 · proof | |
| Free cash flow | -$14.2 million | -$21.1 million | 10-K 2024-04-01 · proof | |
| Total assets | $108.5 million | $395.6 million | -72.6% | 10-K 2024-04-01 · proof |
| Total liabilities | $266.5 million | $302 million | -11.8% | 10-Q 2024-05-14 · proof |
| Cash and cash equivalents | $30 million | $37.5 million | -20.1% | 10-K 2024-04-01 · proof |
- What was Acorda Therapeutics, Inc.'s revenue in fiscal 2023?
- Acorda Therapeutics, Inc. reported revenue of $117.6 million for fiscal 2023 (the year ended Dec 31, 2023), against $118.6 million the year before (-0.8%). Source: the 10-K filed with the SEC on Apr 1, 2024. SEC
- What was Acorda Therapeutics, Inc.'s gross profit in fiscal 2023?
- Acorda Therapeutics, Inc. reported gross profit of $102.4 million for fiscal 2023 (the year ended Dec 31, 2023), against $88.2 million the year before (+16%). Source: the 10-K filed with the SEC on Apr 1, 2024. SEC
- What was Acorda Therapeutics, Inc.'s operating income in fiscal 2023?
- Acorda Therapeutics, Inc. reported operating income of -$265 million for fiscal 2023 (the year ended Dec 31, 2023), against -$35.3 million the year before. Source: the 10-K filed with the SEC on Apr 1, 2024. SEC
- What was Acorda Therapeutics, Inc.'s net income in fiscal 2023?
- Acorda Therapeutics, Inc. reported net income of -$252.9 million for fiscal 2023 (the year ended Dec 31, 2023), against -$65.9 million the year before. Source: the 10-K filed with the SEC on Apr 1, 2024. SEC
- What was Acorda Therapeutics, Inc.'s cash from operating activities in fiscal 2023?
- Acorda Therapeutics, Inc. reported cash from operating activities of -$14 million for fiscal 2023 (the year ended Dec 31, 2023), against -$20.9 million the year before. Source: the 10-K filed with the SEC on Apr 1, 2024. SEC
- What was Acorda Therapeutics, Inc.'s free cash flow in fiscal 2023?
- Acorda Therapeutics, Inc. reported free cash flow of -$14.2 million for fiscal 2023 (the year ended Dec 31, 2023), against -$21.1 million the year before. Source: the 10-K filed with the SEC on Apr 1, 2024. SEC
- What are Acorda Therapeutics, Inc.'s total assets?
- As of Dec 31, 2023, Acorda Therapeutics, Inc. reported total assets of $108.5 million, against $395.6 million a year earlier (-72.6%). Source: the 10-K filed with the SEC on Apr 1, 2024. SEC
- What are Acorda Therapeutics, Inc.'s total liabilities?
- As of Dec 31, 2023, Acorda Therapeutics, Inc. reported total liabilities of $266.5 million, against $302 million a year earlier (-11.8%). Source: the 10-Q filed with the SEC on May 14, 2024 (restated). SEC
- What are Acorda Therapeutics, Inc.'s cash and cash equivalents?
- As of Dec 31, 2023, Acorda Therapeutics, Inc. reported cash and cash equivalents of $30 million, against $37.5 million a year earlier (-20.1%). Source: the 10-K filed with the SEC on Apr 1, 2024. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1008848&period_type=annual&limit=5"Information only, not investment advice.